Why are patients with malignant lymphomas excluded from clinical trials? The experience of an oncology institute in Italy

Author： Serraino D. Zagonel V. Bordonaro R. Franceschi S.

Publisher： Elsevier

ISSN： 0959-8049

Source： European Journal of Cancer, Vol.34, Iss.3, 1998-02, pp. : 427-428

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Practicalities and ethics of running clinical trials in paediatric oncology- the UK experience

By Estlin E.J. Ablett S.

European Journal of Cancer, Vol. 37, Iss. 11, 2001-07 ,pp. : 1394-1401

Elsevier

Access to resources Recommend Favorite

Clinical Trials in Oncology and Defining Benefit

The Oncologist, Vol. 23, Iss. 1, 2018-01 ,pp. : 135-135

John Wiley & Sons Inc

Access to resources Recommend Favorite

Occult Breast Lesion Localization plus Sentinel Node Biopsy (SNOLL): Experience with 959 Patients at the European Institute of Oncology

By Monti Simonetta

Annals of Surgical Oncology, Vol. 14, Iss. 10, 2007-10 ,pp. : 2928-2931

Springer Publishing Company

Access to resources Recommend Favorite

Bisphosphonates in Oncology: Focus on Clinical Experience with Pamidronate

By Body Jean-Jacques

American Journal of Cancer, Vol. 4, Iss. 5, 2005-01 ,pp. : 293-305

Adis International

Access to resources Recommend Favorite

Phase II Clinical Trials in Oncology: Strengths and Limitations of Two-Stage Designs

By Schlesselman James Reis Isildinha

Cancer Investigation, Vol. 24, Iss. 4, 2006-07 ,pp. : 404-412

Informa Healthcare

Access to resources Recommend Favorite